SinoTau
Integrated solutions in radiopharmaceutical R&D for early prevention, diagnosis, and treatment globally.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* |
| CNY1.1b | Series E |
| Total Funding | 000k | ||
Related Content
Sinotau Pharmaceutical Group, founded in 2005, focuses on providing integrated solutions for early prevention, diagnosis, and treatment of diseases through advanced radiopharmaceutical research and development (R&D). The company operates primarily in the healthcare sector, targeting both the Chinese market and international markets. Sinotau serves a diverse range of clients including hospitals, research institutions, and healthcare providers. Its business model revolves around the development, manufacturing, and distribution of radiopharmaceuticals, which are specialized drugs that contain radioactive substances used for diagnosis or treatment of diseases. The company generates revenue through the sale of these radiopharmaceutical products and by offering related services such as clinical academic promotion and quality manufacturing processes.
Keywords: radiopharmaceuticals, early prevention, diagnosis, treatment, healthcare, R&D, manufacturing, clinical promotion, China, global.